Cargando…
Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib
BACKGROUND: Aicardi-Goutières syndrome (AGS) is a rare hereditary early-onset encephalopathy characterized by upregulation of the type I interferon pathway, poorly responsive to conventional immunosuppression. CASE PRESENTATION: We describe a 7-year-old Chinese boy who developed symptoms at the age...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571391/ https://www.ncbi.nlm.nih.gov/pubmed/37828538 http://dx.doi.org/10.1186/s12969-023-00899-4 |
_version_ | 1785119983642083328 |
---|---|
author | Wang, Wei Wang, Wei Peng, Siming Gao, Sihao Quan, Meiying Gou, Lijuan Wang, Changyan Sun, Zhixing Li, Zhuo Lian, Dongmei Song, Hongmei |
author_facet | Wang, Wei Wang, Wei Peng, Siming Gao, Sihao Quan, Meiying Gou, Lijuan Wang, Changyan Sun, Zhixing Li, Zhuo Lian, Dongmei Song, Hongmei |
author_sort | Wang, Wei |
collection | PubMed |
description | BACKGROUND: Aicardi-Goutières syndrome (AGS) is a rare hereditary early-onset encephalopathy characterized by upregulation of the type I interferon pathway, poorly responsive to conventional immunosuppression. CASE PRESENTATION: We describe a 7-year-old Chinese boy who developed symptoms at the age of 6 months. He presented with a chilblain-like rash, leukopenia, neutropenia, elevated liver enzymesgrowth retardation, microcephaly, elevated acute phase reactants, intracranial calcification and leukodystrophy. At the age of 3 years old, whole-exome sequencing confirmed a de novo heterozygous gain-of-function mutation, c.1016 C > A (p.Ala339Asp), in the IFIH1 gene, and he was diagnosed with AGS7. He was treated with ruxolitinib accompanied by steroids and thalidomide for about four years. The rash, hematological manifestations, and the liver function were all improved, but the erythrocyte sedimentation rate remained consistently elevated until the addition of tocilizumab, a monoclonal antibody against interleukin 6. CONCLUSIONS: Ruxolitinib was not successful in suppressing the inflammatory process, and tocilizumab produced highly encouraging results in reducing the inflammatory reaction of AGS. The study makes a significant contribution to the literature because we may found a potential alternative therapeutic option for AGS. |
format | Online Article Text |
id | pubmed-10571391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105713912023-10-14 Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib Wang, Wei Wang, Wei Peng, Siming Gao, Sihao Quan, Meiying Gou, Lijuan Wang, Changyan Sun, Zhixing Li, Zhuo Lian, Dongmei Song, Hongmei Pediatr Rheumatol Online J Case Report BACKGROUND: Aicardi-Goutières syndrome (AGS) is a rare hereditary early-onset encephalopathy characterized by upregulation of the type I interferon pathway, poorly responsive to conventional immunosuppression. CASE PRESENTATION: We describe a 7-year-old Chinese boy who developed symptoms at the age of 6 months. He presented with a chilblain-like rash, leukopenia, neutropenia, elevated liver enzymesgrowth retardation, microcephaly, elevated acute phase reactants, intracranial calcification and leukodystrophy. At the age of 3 years old, whole-exome sequencing confirmed a de novo heterozygous gain-of-function mutation, c.1016 C > A (p.Ala339Asp), in the IFIH1 gene, and he was diagnosed with AGS7. He was treated with ruxolitinib accompanied by steroids and thalidomide for about four years. The rash, hematological manifestations, and the liver function were all improved, but the erythrocyte sedimentation rate remained consistently elevated until the addition of tocilizumab, a monoclonal antibody against interleukin 6. CONCLUSIONS: Ruxolitinib was not successful in suppressing the inflammatory process, and tocilizumab produced highly encouraging results in reducing the inflammatory reaction of AGS. The study makes a significant contribution to the literature because we may found a potential alternative therapeutic option for AGS. BioMed Central 2023-10-12 /pmc/articles/PMC10571391/ /pubmed/37828538 http://dx.doi.org/10.1186/s12969-023-00899-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Wang, Wei Wang, Wei Peng, Siming Gao, Sihao Quan, Meiying Gou, Lijuan Wang, Changyan Sun, Zhixing Li, Zhuo Lian, Dongmei Song, Hongmei Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib |
title | Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib |
title_full | Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib |
title_fullStr | Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib |
title_full_unstemmed | Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib |
title_short | Tocilizumab reduces the unmanageable inflammatory reaction of a patient with Aicardi-Goutières syndrome type 7 during treatment with ruxolitinib |
title_sort | tocilizumab reduces the unmanageable inflammatory reaction of a patient with aicardi-goutières syndrome type 7 during treatment with ruxolitinib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571391/ https://www.ncbi.nlm.nih.gov/pubmed/37828538 http://dx.doi.org/10.1186/s12969-023-00899-4 |
work_keys_str_mv | AT wangwei tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib AT wangwei tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib AT pengsiming tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib AT gaosihao tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib AT quanmeiying tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib AT goulijuan tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib AT wangchangyan tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib AT sunzhixing tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib AT lizhuo tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib AT liandongmei tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib AT songhongmei tocilizumabreducestheunmanageableinflammatoryreactionofapatientwithaicardigoutieressyndrometype7duringtreatmentwithruxolitinib |